文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

Ⅰ型呼吸衰竭患者经鼻高流量氧疗失败预测模型的开发与验证

[Development and validation of a predictive model for high-flow nasal cannula oxygen therapy failure in patients with type I respiratory failure].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2026-01-01
一句话结论基于急性肾损伤、血乳酸、氧合指数和GCS构建的列线图模型,可预测Ⅰ型呼吸衰竭患者HFNC失败风险,训练集AUC 0.844、验证集AUC 0.794。

该回顾性观察研究纳入2019年1月至2024年12月徐州医科大学附属医院ICU收治的700例接受HFNC治疗的Ⅰ型呼吸衰竭患者,按7∶3随机分为训练集和验证集,以气管插管和/或治疗期间死亡定义HFNC失败(失败率14.1%)。多因素logistic回归显示急性肾损伤(OR=2.113)和血乳酸升高(OR=1.148)为独立危险因素,氧合指数升高(OR=0.973)和GCS评分升高(OR=0.815)为独立保护因素,据此构建列线图模型。训练集AUC 0.844、验证集AUC 0.794,Hosmer-Lemeshow检验提示拟合良好,校准曲线一致性好,DCA显示较宽阈值概率范围内有良好临床净获益。作者认为该模型有助于早期识别HFNC失败高危患者并优化临床决策。

要点

  • 700例Ⅰ型呼吸衰竭接受HFNC患者中99例失败(气管插管和/或治疗期间死亡),失败率14.1%。
  • 急性肾损伤(OR=2.113,95%CI 1.159-3.854,P=0.015)与血乳酸升高(OR=1.148,95%CI 1.027-1.283,P=0.015)为HFNC失败独立危险因素。
  • 氧合指数升高(OR=0.973,95%CI 0.963-0.983,P<0.001)与GCS评分升高(OR=0.815,95%CI 0.760-0.874,P<0.001)为独立保护因素。
  • 列线图模型训练集AUC 0.844(95%CI 0.794-0.895),验证集AUC 0.794(95%CI 0.706-0.881)。
  • cutoff值0.160时训练集敏感度73.9%、特异度81.0%、准确率80.0%;验证集敏感度60.0%、特异度82.8%、准确率79.5%。

适用人群与场景

  • 2019年1月至2024年12月徐州医科大学附属医院ICU收治的Ⅰ型呼吸衰竭并接受HFNC治疗的患者。
  • 以是否发生HFNC失败(治疗期间气管插管和/或死亡)分为成功组(601例)和失败组(99例)。

诊断标准与关键阈值

  • HFNC失败定义:治疗期间发生气管插管和/或死亡。
  • 模型预测cutoff值为0.160,高于此阈值提示HFNC失败风险增高。

红旗征与不能漏的情况

  • 合并急性肾损伤的Ⅰ型呼吸衰竭患者HFNC失败风险升高(OR=2.113,95%CI 1.159-3.854,P=0.015)。
  • 血乳酸水平升高与HFNC失败风险独立相关(OR=1.148,95%CI 1.027-1.283,P=0.015)。
  • 氧合指数较低与HFNC失败风险独立相关(OR=0.973,95%CI 0.963-0.983,P<0.001)。
  • GCS评分较低与HFNC失败风险独立相关(OR=0.815,95%CI 0.760-0.874,P<0.001)。

研究设计与关键结果

  • 研究类型:回顾性观察研究,纳入700例Ⅰ型呼吸衰竭接受HFNC治疗的ICU患者,HFNC成功601例、失败99例,失败率14.1%。
  • 与成功组相比,失败组身高、冠心病比例、血钠、氧合指数、GCS评分及接受人血白蛋白治疗比例较低,急性肾损伤发生率、心率、呼吸频率、血尿素氮、血肌酐、血乳酸、SOFA评分、APACHEⅡ评分较高,凝血酶原时间较长(均P<0.05)。
  • 多因素logistic回归:急性肾损伤(OR=2.113,95%CI 1.159-3.854,P=0.015)和血乳酸升高(OR=1.148,95%CI 1.027-1.283,P=0.015)为独立危险因素;氧合指数升高(OR=0.973,95%CI 0.963-0.983,P<0.001)和GCS评分升高(OR=0.815,95%CI 0.760-0.874,P<0.001)为独立保护因素。
  • 基于上述4个独立预测因子构建列线图模型,训练集AUC 0.844(95%CI 0.794-0.895),验证集AUC 0.794(95%CI 0.706-0.881)。
  • cutoff值0.160时,训练集敏感度73.9%、特异度81.0%、准确率80.0%;验证集敏感度60.0%、特异度82.8%、准确率79.5%。
  • Hosmer-Lemeshow检验训练集χ²=8.636(P=0.374)、验证集χ²=6.652(P=0.575),校准曲线显示预测概率与实际观察一致性良好;DCA显示较宽阈值概率范围内有良好临床净获益。

证据类型、等级与局限

  • 证据类型:回顾性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,基于急性肾损伤、血乳酸水平、氧合指数和GCS评分构建的列线图模型对Ⅰ型呼吸衰竭患者HFNC失败风险具有良好预测性能,可为早期识别高危患者和优化临床决策提供参考。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the independent risk factors for failure of high-flow nasal cannula oxygen therapy (HFNC) in patients with type I respiratory failure, and to establish and validate an effective risk prediction model.

METHODS: A retrospective observational study was conducted, Patients with type I respiratory failure who received HFNC treatment in the intensive care unit (ICU) of the Affiliated Hospital of Xuzhou Medical University from January 2019 to December 2024 were selected as the research subjects. Clinical data within 24 hours after admission to the ICU were collected, including demographic information and general conditions, underlying diseases, early acute organ dysfunction, vital signs, laboratory examinations, disease severity scores, and treatment measures. Patients were divided into the HFNC success group and the HFNC failure group based on whether HFNC failure (endotracheal intubation and/or death during treatment) occurred. The overall cohort was randomly divided at a ratio of 7 : 3 into a training set and a validation set. Multivariate logistic regression analysis was used to screen independent predictors of HFNC failure, and a nomogram prediction model was constructed accordingly. The receiver operator characteristic curve (ROC curve), Hosmer-Lemeshow goodness-of-fit test, calibration curve, and decision curve analysis (DCA) were used to evaluate the model's discrimination, calibration, and clinical utility.

RESULTS: A total of 700 patients with type I respiratory failure were included, of whom 601 experienced HFNC success and 99 experienced HFNC failure, with a failure rate of 14.1%. Compared with the HFNC success group, patients in the HFNC failure group had lower height, proportion of coronary heart disease, serum sodium, oxygenation index, Glasgow Coma Score (GCS), and proportion of patients receiving human albumin, while exhibiting significantly higher incidence of acute kidney injury (AKI), heart rate, respiratory rate, blood urea nitrogen level, serum creatinine level, blood lactate level, Sequential Organ Failure Assessment (SOFA) score, and Acute Physiology and Chronic Health Evaluation II(APACHE II) score, as well as longer prothrombin time (all P<0.05). Multivariate logistic regression analysis showed that the presence of AKI [odds ratio (OR)=2.113, 95% confidence interval (95%CI) was 1.159-3.854, P=0.015] and elevated blood lactate level (OR=1.148, 95%CI was 1.027-1.283, P=0.015) were independent risk factors for HFNC failure, while elevated oxygenation index (OR=0.973, 95%CI was 0.963-0.983, P<0.001) and higher GCS score (OR=0.815, 95%CI was 0.760-0.874, P<0.001) were independent protective factors. Based on these four independent predictors, a nomogram prediction model was established. The ROC curves showed that the area under the curve (AUC) of the training set and validation set were 0.844 (95%CI was 0.794-0.895) and 0.794 (95%CI was 0.706-0.881), respectively. At a cutoff value of 0.160, the sensitivities were 73.9% and 60.0%, the specificities were 81.0% and 82.8%, and the accuracies were 80.0% and 79.5% in the training set and validation set, respectively. The Hosmer-Lemeshow test showed good fit for the model in both the training set (χ 2=8.636, P=0.374) and validation set (χ 2=6.652, P=0.575). The calibration curves indicated good agreement between the model predicted probabilities and the actual observations. DCA demonstrated that the model exhibited good clinical net benefit over a wide range of threshold probabilities.

CONCLUSIONS: The nomogram model constructed based on AKI, blood lactate level, oxygenation index, and GCS score has good predictive performance for the risk of HFNC failure in patients with type I respiratory failure, providing a reference for early identification of high-risk patients and optimization of clinical decision-making.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Ma F, Chao Y, Xu L, et al. [Development and validation of a predictive model for high-flow nasal cannula oxygen therapy failure in patients with type I respiratory failure]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 42875239. doi:10.3760/cma.j.cn121430-20260423-00202

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。